Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed (IPPEM)

Primary Outcome Measures

• Association between PPI consumption and pemetrexed-related hematological toxicity (grade ≥ 3) [ Time Frame: Day 0 ]
  The hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria

Eligibility Criteria

Inclusion Criteria

Patients who receive a pemetrexed-based chemotherapy regimen for the treatment of non-small cell lung cancer (NSCLC) or mesothelioma,

Patients who consent to participate,

Patients for whom it is possible to characterize the consumption of proton pump inhibitors with name of the PPI

Exclusion Criteria

Patients who receive pemetrexed out of intravenous of for another condition than NSCLC or mesothelioma

Patients under 18 or who refused the participation in the data collection,

Patient previously treated by a pemetrexed-based chemotherapy,

Patients who first receive a pemetrexed-based regimen with an initial dose adjustment (<500 mg/m²) and dosage.